yves Dauvilliers

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7508105/publications.pdf

Version: 2024-02-01

393 papers	23,350 citations	6254 80 h-index	13379 130 g-index
438 all docs	438 docs citations	438 times ranked	14577 citing authors

#	Article	IF	Citations
1	National Sleep Foundation's sleep quality recommendations: first report. Sleep Health, 2017, 3, 6-19.	2.5	729
2	Narcolepsy with cataplexy. Lancet, The, 2007, 369, 499-511.	13.7	647
3	Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain, 2019, 142, 744-759.	7.6	636
4	Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology, 2001, 57, 2029-2033.	1.1	369
5	Narcolepsy â€" clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nature Reviews Neurology, 2019, 15, 519-539.	10.1	364
6	A singleâ€question screen for rapid eye movement sleep behavior disorder: A multicenter validation study. Movement Disorders, 2012, 27, 913-916.	3.9	311
7	Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2017, 16, 200-207.	10.2	306
8	Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurology, The, 2013, 12, 1068-1075.	10.2	301
9	REM sleep behaviour disorder. Nature Reviews Disease Primers, 2018, 4, 19.	30.5	290
10	CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1667-1673.	1.9	274
11	A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Annals of Neurology, 2019, 85, 359-370.	5.3	274
12	Elevated Tribbles homolog 2â€"specific antibody levels in narcolepsy patients. Journal of Clinical Investigation, 2010, 120, 713-719.	8.2	263
13	An inverse agonist of the histamine H3 receptor improves wakefulness in narcolepsy: Studies in orexinâ^'/â^' mice and patients. Neurobiology of Disease, 2008, 30, 74-83.	4.4	254
14	Polysomnographic diagnosis of idiopathic REM sleep behavior disorder. Movement Disorders, 2010, 25, 2044-2051.	3.9	253
15	Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: A multicenter study. Annals of Neurology, 2015, 77, 830-839.	5.3	248
16	Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1135-1145.	5.6	237
17	Insomnia and Daytime Sleepiness Are Risk Factors for Depressive Symptoms in the Elderly. Sleep, 2011, 34, 1103-1110.	1.1	226
18	Insomnia Symptoms in Older Adults: Associated Factors and Gender Differences. American Journal of Geriatric Psychiatry, 2011, 19, 88-97.	1.2	214

#	ARTICLE	IF	CITATIONS
19	Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study. Sleep, 2019, 42, .	1.1	213
20	ImmunoChip Study Implicates Antigen Presentation to T Cells in Narcolepsy. PLoS Genetics, 2013, 9, e1003270.	3.5	206
21	Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain, 2013, 136, 2486-2496.	7.6	203
22	Neural network analysis of sleep stages enables efficient diagnosis of narcolepsy. Nature Communications, 2018, 9, 5229.	12.8	194
23	Energy cost of walking and gait instability in healthy 65- and 80-yr-olds. Journal of Applied Physiology, 2003, 95, 2248-2256.	2.5	193
24	Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. Lancet Neurology, The, 2017, 16, 898-907.	10.2	191
25	Post-H1N1 Narcolepsy-Cataplexy. Sleep, 2010, 33, 1428-1430.	1.1	187
26	Narcolepsy. Nature Reviews Disease Primers, 2017, 3, 16100.	30.5	185
27	Predictors of Hypocretin (Orexin) Deficiency in Narcolepsy Without Cataplexy. Sleep, 2012, 35, 1247-1255.	1.1	182
28	Clinical, polysomnographic and genomeâ€wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study. Journal of Sleep Research, 2013, 22, 482-495.	3.2	182
29	Measures of functional outcomes, work productivity, and quality of life from a randomized, phase 3 study of solriamfetol in participants with narcolepsy. Sleep Medicine, 2020, 67, 128-136.	1.6	182
30	Hypertension and sleep: Overview of a tight relationship. Sleep Medicine Reviews, 2014, 18, 509-519.	8.5	181
31	Excessive Sleepiness is Predictive of Cognitive Decline in the Elderly. Sleep, 2012, 35, 1201-1207.	1.1	178
32	Insomnia, anxiety, and depression during the COVID-19 pandemic: an international collaborative study. Sleep Medicine, 2021, 87, 38-45.	1.6	177
33	Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nature Genetics, 2010, 42, 786-789.	21.4	170
34	REM Sleep Characteristics in Narcolepsy and REM Sleep Behavior Disorder. Sleep, 2007, 30, 844-849.	1.1	169
35	DQB1 Locus Alone Explains Most of the Risk and Protection in Narcolepsy with Cataplexy in Europe. Sleep, 2014, 37, 19-25.	1.1	164
36	Genome-Wide Association Study Identifies Novel Restless Legs Syndrome Susceptibility Loci on 2p14 and 16q12.1. PLoS Genetics, 2011, 7, e1002171.	3.5	163

#	Article	IF	Citations
37	Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Brain, 2011, 134, 3480-3492.	7.6	159
38	Disrupted Nighttime Sleep in Narcolepsy. Journal of Clinical Sleep Medicine, 2013, 09, 955-965.	2.6	156
39	Cataplexyâ€"clinical aspects, pathophysiology and management strategy. Nature Reviews Neurology, 2014, 10, 386-395.	10.1	153
40	Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Annals of Neurology, 2004, 56, 905-908.	5.3	152
41	Insomnia in patients with neurodegenerative conditions. Sleep Medicine, 2007, 8, S27-S34.	1.6	152
42	Excessive Daytime Sleepiness Is an Independent Risk Indicator for Cardiovascular Mortality in Community-Dwelling Elderly. Stroke, 2009, 40, 1219-1224.	2.0	152
43	Psychological health in central hypersomnias: the French Harmony study. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 636-641.	1.9	148
44	Challenges in Diagnosing Narcolepsy without Cataplexy: A Consensus Statement. Sleep, 2014, 37, 1035-1042.	1.1	145
45	Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder. Brain, 2014, 137, 3122-3128.	7.6	134
46	NREM sleep parasomnias as disorders of sleep-state dissociation. Nature Reviews Neurology, 2018, 14, 470-481.	10.1	132
47	Effect of age on MSLT results in patients with narcolepsyâ€"cataplexy. Neurology, 2004, 62, 46-50.	1.1	127
48	HLA-DPB1 and HLA Class I Confer Risk of and Protection from Narcolepsy. American Journal of Human Genetics, 2015, 96, 136-146.	6.2	125
49	Clinical aspects and pathophysiology of narcolepsy. Clinical Neurophysiology, 2003, 114, 2000-2017.	1.5	122
50	Excessive sleep duration and quality of life. Annals of Neurology, 2013, 73, 785-794.	5.3	120
51	Attention-Deficit/Hyperactivity Disorder (ADHD) Symptoms in Pediatric Narcolepsy: A Cross-Sectional Study. Sleep, 2015, 38, 1285-1295.	1.1	120
52	Diagnosis of central disorders of hypersomnolence: A reappraisal by European experts. Sleep Medicine Reviews, 2020, 52, 101306.	8.5	119
53	GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder. Annals of Clinical and Translational Neurology, 2015, 2, 941-945.	3.7	117
54	Recurrent hypersomnia: A review of 339 cases. Sleep Medicine Reviews, 2011, 15, 247-257.	8.5	116

#	ARTICLE	IF	CITATIONS
55	Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain, 2013, 136, 3787-3795.	7.6	113
56	Family studies in insomnia. Journal of Psychosomatic Research, 2005, 58, 271-278.	2.6	111
57	Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): A systematic review and meta-analysis of randomized controlled trials. Sleep Medicine Reviews, 2012, 16, 431-443.	8.5	111
58	Effect of cognitive behavioural therapy for insomnia on sleep architecture and sleep EEG power spectra in psychophysiological insomnia. Journal of Sleep Research, 2004, 13, 385-393.	3.2	107
59	A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France. Movement Disorders, 2007, 22, 1567-1572.	3.9	106
60	Hypersomnia and depressive symptoms: methodological and clinical aspects. BMC Medicine, 2013, 11, 78.	5.5	106
61	Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Medicine, 2015, 16, 9-18.	1.6	106
62	CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10956-10961.	7.1	106
63	High-dimensional single-cell analysis reveals the immune signature of narcolepsy. Journal of Experimental Medicine, 2016, 213, 2621-2633.	8.5	106
64	Retinoic Acid Signaling Affects Cortical Synchrony During Sleep. Science, 2005, 310, 111-113.	12.6	102
65	Periodic leg movements during sleep and wakefulness in narcolepsy. Journal of Sleep Research, 2007, 16, 333-339.	3.2	102
66	Functional Impairment in Adult Sleepwalkers: A Case-Control Study. Sleep, 2013, 36, 345-351.	1.1	101
67	Operational Definitions and Algorithms for Excessive Sleepiness in the General Population. Archives of General Psychiatry, 2012, 69, 71.	12.3	100
68	Arousal Reactions in Sleepwalking and Night Terrors in Adults: The Role of Respiratory Events. Sleep, 2002, 25, 32-36.	1.1	99
69	Restless legs syndrome. Current Opinion in Pulmonary Medicine, 2013, 19, 594-600.	2.6	97
70	Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia in narcolepsy. Sleep Medicine, 2013, 14, 775-781.	1.6	94
71	Testâ€“Retest Reliability of the Multiple Sleep Latency Test in Central Disorders of Hypersomnolence. Sleep, 2017, 40, .	1.1	94
72	Family History of Insomnia in a Population-Based Sample. Sleep, 2007, 30, 1739-1745.	1.1	93

#	ARTICLE	IF	CITATIONS
73	Insomnia in central neurologic diseases â€“ Occurrence and management. Sleep Medicine Reviews, 2011, 15, 369-378.	8.5	91
74	Comorbidity and medication in REM sleep behavior disorder. Neurology, 2014, 82, 1076-1079.	1.1	90
75	Autonomic symptoms in idiopathic REM behavior disorder: a multicentre caseâ€“control study. Journal of Neurology, 2014, 261, 1112-1118.	3.6	90
76	Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology, 2009, 73, 1333-1334.	1.1	89
77	Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder. Annals of Neurology, 2020, 87, 347-356.	5.3	88
78	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. Clinical and Translational Allergy, 2019, 9, 44.	3.2	87
79	The clinical spectrum of childhood narcolepsy. Sleep Medicine Reviews, 2018, 38, 70-85.	8.5	86
80	Non-Dipping Blood Pressure Profile in Narcolepsy with Cataplexy. PLoS ONE, 2012, 7, e38977.	2.5	85
81	Normal Cerebrospinal Fluid Histamine and tele-Methylhistamine Levels in Hypersomnia Conditions. Sleep, 2012, 35, 1359-1366.	1.1	83
82	Treatment Options for Narcolepsy. CNS Drugs, 2016, 30, 369-379.	5.9	83
83	Normal CSF Hypocretin-1 (Orexin A) Levels in Dementia with Lewy Bodies Associated with Excessive Daytime Sleepiness. European Neurology, 2004, 52, 73-76.	1.4	82
84	Daytime Sleepiness and REM Sleep Characteristics in Myotonic Dystrophy: A Case-Control Study. Sleep, 2011, 34, 165-170.	1.1	82
85	SMPD1 mutations, activity, and Î±â€synuclein accumulation in Parkinson's disease. Movement Disorders, 2019, 34, 526-535.	3.9	81
86	Restless legs syndrome. Nature Reviews Disease Primers, 2021, 7, 80.	30.5	81
87	Novel Approach Identifies SNPs in SLC2A10 and KCNK9 with Evidence for Parent-of-Origin Effect on Body Mass Index. PLoS Genetics, 2014, 10, e1004508.	3.5	80
88	Interactions of the histamine and hypocretin systems in CNS disorders. Nature Reviews Neurology, 2015, 11, 401-413.	10.1	80
89	Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation. The Lancet Child and Adolescent Health, 2018, 2, 483-494.	5.6	78
90	Age-related changes in sleep in inbred mice are genotype dependent. Neurobiology of Aging, 2012, 33, 195.e13-195.e26.	3.1	77

#	Article	IF	Citations
91	Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: A long-term chart review. Sleep Medicine, 2013, 14, 30-36.	1.6	76
92	Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process. Neurobiology of Aging, 2017, 53, 59-66.	3.1	76
93	Impact of Obesity in Children with Narcolepsy. CNS Neuroscience and Therapeutics, 2013, 19, 521-528.	3.9	74
94	Measurement of narcolepsy symptoms. Neurology, 2017, 88, 1358-1365.	1.1	74
95	Hypothalamic Immunopathology in Anti-Maâ€“Associated Diencephalitis With Narcolepsy-Cataplexy. JAMA Neurology, 2013, 70, 1305-10.	9.0	73
96	Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease. Annals of Neurology, 2021, 90, 62-75.	5.3	73
97	Myotonic dystrophy type 1, daytime sleepiness and REM sleep dysregulation. Sleep Medicine Reviews, 2012, 16, 539-545.	8.5	72
98	Excessive daytime sleepiness and vascular events: The Three City Study. Annals of Neurology, 2012, 71, 661-667.	5.3	71
99	From Phenomenology to Neurophysiological Understanding of Hallucinations in Children and Adolescents. Schizophrenia Bulletin, 2014, 40, S221-S232.	4.3	71
100	Histamine: neural circuits and new medications. Sleep, 2019, 42, .	1.1	71
101	Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. Sleep Medicine, 2011, 12, 550-556.	1.6	70
102	POLLAR: Impact of air POLLution on Asthma and Rhinitis; a European Institute of Innovation and Technology Health (EIT Health) project. Clinical and Translational Allergy, 2018, 8, 36.	3.2	70
103	Determinants of excessive daytime sleepiness in a French communityâ€dwelling elderly population. Journal of Sleep Research, 2007, 16, 364-371.	3.2	69
104	The burden of narcolepsy with cataplexy: How disease history and clinical features influence socio-economic outcomes. Sleep Medicine, 2012, 13, 1293-1300.	1.6	69
105	Daytime Sleepiness and Myotonic Dystrophy. Current Neurology and Neuroscience Reports, 2013, 13, 340.	4.2	67
106	European guideline and expert statements on the management of narcolepsy in adults and children. European Journal of Neurology, 2021, 28, 2815-2830.	3.3	67
107	The improvement of movement and speech during rapid eye movement sleep behaviour disorder in multiple system atrophy. Brain, 2011, 134, 856-862.	7.6	66
108	<scp>K</scp>leineâ€“<scp>L</scp>evin syndrome in 120 patients: Differential diagnosis and long episodes. Annals of Neurology, 2015, 77, 529-540.	5.3	66

#	Article	IF	Citations
109	Catechol-O-methyltransferase, dopamine, and sleep-wake regulation. Sleep Medicine Reviews, 2015, 22, 47-53.	8.5	66
110	Narcolepsy-Associated HLA Class I Alleles Implicate Cell-Mediated Cytotoxicity. Sleep, 2016, 39, 581-587.	1.1	66
111	Diagnostic criteria for disorders of arousal: A videoâ€polysomnographic assessment. Annals of Neurology, 2018, 83, 341-351.	5.3	66
112	Genetic, Structural, and Functional Evidence Link TMEM175 to Synucleinopathies. Annals of Neurology, 2020, 87, 139-153.	5.3	65
113	Month of Birth as a Risk Factor for Narcolepsy. Sleep, 2003, 26, 663-665.	1.1	64
114	No effect on cognitive function from daily mobile phone use. Bioelectromagnetics, 2005, 26, 102-108.	1.6	64
115	Fatigue and daytime sleepiness in patients with myotonic dystrophy type 1: To lump or split?. Neuromuscular Disorders, 2009, 19, 397-402.	0.6	64
116	Hypnotics and mortality in an elderly general population: a 12-year prospective study. BMC Medicine, 2013, 11, 212.	5.5	64
117	Daytime Sleepiness in Parkinsonâ€™s Disease: A Reappraisal. PLoS ONE, 2014, 9, e107278.	2.5	64
118	Incidence, worsening and risk factors of daytime sleepiness in a population-based 5-year longitudinal study. Scientific Reports, 2017, 7, 1372.	3.3	64
119	Recent advances in treatment for narcolepsy. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641987562.	3.5	64
120	Quality of Life in Children with Narcolepsy. CNS Neuroscience and Therapeutics, 2014, 20, 763-771.	3.9	63
121	Genes for normal sleep and sleep disorders. Annals of Medicine, 2005, 37, 580-589.	3.8	62
122	Restless Legs Syndrome is Frequent in Narcolepsy with Cataplexy Patients. Sleep, 2010, 33, 689-694.	1.1	62
123	Alternative diagnostic criteria for idiopathic hypersomnia: A 32â€hour protocol. Annals of Neurology, 2018, 83, 235-247.	5.3	62
124	Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder. Neurology, 2020, 94, e2222-e2232.	1.1	62
125	Car Crashes and Central Disorders of Hypersomnolence: A French Study. PLoS ONE, 2015, 10, e0129386.	2.5	62
126	Depressive feelings in children with narcolepsy. Sleep Medicine, 2014, 15, 309-314.	1.6	61

#	Article	IF	Citations
127	Hypersomnolence, Hypersomnia, and Mood Disorders. Current Psychiatry Reports, 2017, 19, 13.	4.5	61
128	Executive Control of Attention in Narcolepsy. PLoS ONE, 2012, 7, e33525.	2.5	59
129	Follow-up of four narcolepsy patients treated with intravenous immunoglobulins. Annals of Neurology, 2006, 60, 153-153.	5.3	58
130	Decision Making in Narcolepsy with Cataplexy. Sleep, 2011, 34, 99-104.	1.1	58
131	Management of narcolepsy during pregnancy. Sleep Medicine, 2013, 14, 367-376.	1.6	58
132	Narcolepsy as an adverse event following immunization: Case definition and guidelines for data collection, analysis and presentation. Vaccine, 2013, 31, 994-1007.	3.8	58
133	From state dissociation to status dissociatus. Sleep Medicine Reviews, 2016, 28, 5-17.	8.5	56
134	A monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1. Neurology, 2004, 62, 2137-2138.	1.1	55
135	A brain PET study in patients with narcolepsy-cataplexy. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 344-348.	1.9	55
136	Decision-Making, Reward-Seeking Behaviors and Dopamine Agonist Therapy in Restless Legs Syndrome. Sleep, 2013, 36, 1501-1507.	1.1	55
137	A narcolepsy susceptibility locus maps to a 5Mb region of chromosome 21q. Annals of Neurology, 2004, 56, 382-388.	5.3	54
138	Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other origin. Journal of Sleep Research, 2010, 19, 620-623.	3.2	54
139	Family history of idiopathic REM behavior disorder. Neurology, 2013, 80, 2233-2235.	1.1	54
140	Narcolepsy and pregnancy: a retrospective <scp>E</scp>uropean evaluation of 249 pregnancies. Journal of Sleep Research, 2013, 22, 496-512.	3.2	54
141	Impact of Astroglial Connexins on Modafinil Pharmacological Properties. Sleep, 2016, 39, 1283-1292.	1.1	50
142	Comorbidity between central disorders of hypersomnolence and immune-based disorders. Neurology, 2017, 88, 93-100.	1.1	50
143	Aerobic determinants of the decline in preferred walking speed in healthy, active 65- and 80-year-olds. Pflugers Archiv European Journal of Physiology, 2004, 447, 915-921.	2.8	49
144	Differential diagnosis in hypersomnia. Current Neurology and Neuroscience Reports, 2006, 6, 156-162.	4.2	49

#	ARTICLE	IF	CITATIONS
145	Comparing Treatment Effect Measurements in Narcolepsy: The Sustained Attention to Response Task, Epworth Sleepiness Scale and Maintenance of Wakefulness Test. Sleep, 2015, 38, 1051-1058.	1.1	49
146	Insomnia, Daytime Sleepiness and Cardio-Cerebrovascular Diseases in the Elderly: A 6-Year Prospective Study. PLoS ONE, 2013, 8, e56048.	2.5	49
147	Absence of Î³â€aminobutyric acidâ€a receptor potentiation in central hypersomnolence disorders. Annals of Neurology, 2016, 80, 259-268.	5.3	48
148	Lower wake resting sympathetic and cardiovascular activities in narcolepsy with cataplexy. Neurology, 2014, 83, 1080-1086.	1.1	47
149	The European Narcolepsy Network (<scp>EU</scp>â€<scp>NN</scp>) database. Journal of Sleep Research, 2016, 25, 356-364.	3.2	47
150	Depression and Hypersomnia. Sleep Medicine Clinics, 2017, 12, 395-405.	2.6	47
151	Validation of Multiple Sleep Latency Test for the diagnosis of pediatric narcolepsy type 1. Neurology, 2019, 93, e1034-e1044.	1.1	47
152	Measurement of symptoms in idiopathic hypersomnia. Neurology, 2019, 92, e1754-e1762.	1.1	47
153	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	5.7	46
154	Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP. Chest, 2021, 159, 1598-1609.	0.8	46
155	GBA variants in REM sleep behavior disorder. Neurology, 2020, 95, e1008-e1016.	1.1	45
156	Autonomic Response to Periodic Leg Movements during Sleep in Narcolepsy-Cataplexy. Sleep, 2011, 34, 219-223.	1.1	44
157	A multidimensional approach of impulsivity in adult attention deficit hyperactivity disorder. Psychiatry Research, 2015, 227, 290-295.	3.3	44
158	Impact of cytokine in type 1 narcolepsy: Role of pandemic H1N1 vaccination ?. Journal of Autoimmunity, 2015, 60, 20-31.	6.5	44
159	Management of Narcolepsy. Current Treatment Options in Neurology, 2016, 18, 43.	1.8	44
160	European guideline and expert statements on the management of narcolepsy in adults and children. Journal of Sleep Research, 2021, 30, e13387.	3.2	44
161	Molecular genetics and treatment of narcolepsy. Annals of Medicine, 2006, 38, 252-262.	3.8	43
162	Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy. Journal of Sleep Research, 2017, 26, 407-414.	3.2	43

#	ARTICLE	IF	CITATIONS
163	Evening-types show highest increase of sleep and mental health problems during the COVID-19 pandemicâ€"multinational study on 19 267 adults. Sleep, 2022, 45, .	1.1	42
164	Sleep and daytime problems during the COVID-19 pandemic and effects of coronavirus infection, confinement and financial suffering: a multinational survey using a harmonised questionnaire. BMJ Open, 2021, 11, e050672.	1.9	41
165	Increased perfusion in supplementary motor area during a REM sleep behaviour episode. Sleep Medicine, 2011, 12, 531-532.	1.6	40
166	Objective daytime sleepiness in patients with somnambulism or sleep terrors. Neurology, 2014, 83, 2070-2076.	1.1	40
167	Effect of psychostimulants on blood pressure profile and endothelial function in narcolepsy. Neurology, 2018, 90, e479-e491.	1.1	40
168	Histamine and tele-methylhistamine quantification in cerebrospinal fluid from narcoleptic subjects by liquid chromatography tandem mass spectrometry with precolumn derivatization. Analytical Biochemistry, 2011, 409, 28-36.	2.4	39
169	Periodic leg movements during sleep in narcoleptic patients with or without restless legs syndrome. Journal of Sleep Research, 2012, 21, 155-162.	3.2	39
170	Fineâ€Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. Annals of Neurology, 2020, 87, 584-598.	5.3	39
171	Analysis of Heterozygous <scp>PRKN</scp> Variants and Copyâ€Number Variations in Parkinson's Disease. Movement Disorders, 2021, 36, 178-187.	3.9	39
172	Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate) Tj ETQq0 0 0 rgBT /Overlock 10 Tf narcolepsy with cataplexy. Sleep, 2021, 44, .	1.1	39
173	Cardiovascular disorders in narcolepsy: Review of associations and determinants. Sleep Medicine Reviews, 2021, 58, 101440.	8.5	39
174	Pressure Reduction During Exhalation in Sleep Apnea Patients Treated by Continuous Positive Airway Pressure. Chest, 2009, 136, 490-497.	0.8	38
175	Analysis of DNAJC13 mutations in French-Canadian/French cohort of Parkinson's disease. Neurobiology of Aging, 2016, 45, 212.e13-212.e17.	3.1	38
176	High pain frequency in narcolepsy with cataplexy. Sleep Medicine, 2011, 12, 572-577.	1.6	37
177	Suggested immobilization test for diagnosis of restless legs syndrome in Parkinson's disease. Movement Disorders, 2012, 27, 743-749.	3.9	37
178	Pain in Sleepwalking: A Clinical Enigma. Sleep, 2015, 38, 1693-1698.	1.1	37
179	The association between high risk of sleep apnea, comorbidities, and risk of COVID-19: a population-based international harmonized study. Sleep and Breathing, 2021, 25, 849-860.	1.7	37
180	Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. Lancet Neurology, The, 2022, 21, 53-65.	10.2	37

#	ARTICLE	IF	CITATIONS
181	Cerebrospinal fluid and serum cytokine profiles in narcolepsy with cataplexy: A case-control study. Brain, Behavior, and Immunity, 2014, 37, 260-266.	4.1	36
182	From radioimmunoassay to mass spectrometry: a new method to quantify orexin-A (hypocretin-1) in cerebrospinal fluid. Scientific Reports, 2016, 6, 25162.	3.3	36
183	Exploring the clinical features of narcolepsy type 1 versus narcolepsy type 2 from European Narcolepsy Network database with machine learning. Scientific Reports, 2018, 8, 10628.	3.3	36
184	Widespread Hypermetabolism in Symptomatic and Asymptomatic Episodes in Kleine-Levin Syndrome. PLoS ONE, 2014, 9, e93813.	2.5	35
185	French consensus. Management of patients with hypersomnia: Which strategy?. Revue Neurologique, 2017, 173, 8-18.	1.5	35
186	Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy. Sleep, 2017, 40, .	1.1	35
187	Smoking, Alcohol, Drug Use, Abuse and Dependence in Narcolepsy and Idiopathic Hypersomnia: A Case-Control Study. Sleep, 2016, 39, 573-580.	1.1	34
188	Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2016, 68, 434-443.	1.9	33
189	Increased Immune Complexes of Hypocretin Autoantibodies in Narcolepsy. PLoS ONE, 2010, 5, e13320.	2.5	33
190	Impact of acute administration of sodium oxybate on nocturnal sleep polysomnography and on multiple sleep latency test in narcolepsy with cataplexy. Sleep Medicine, 2014, 15, 1046-1054.	1.6	32
191	Hypersomnia. Dialogues in Clinical Neuroscience, 2005, 7, 347-356.	3.7	32
192	Kleineâ€“Levin syndrome in a 14-year-old girl: CSF hypocretin-1 measurements. Sleep Medicine, 2006, 7, 649-651.	1.6	31
193	Sleep Complaints and Metabolic Syndrome in an Elderly Population: The Three-City Study. American Journal of Geriatric Psychiatry, 2015, 23, 818-828.	1.2	31
194	Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder. Movement Disorders, 2018, 33, 1016-1020.	3.9	31
195	Targeted sequencing of Parkinsonâ€™s disease loci genes highlights SYT11, FGF20 and other associations. Brain, 2021, 144, 462-472.	7.6	31
196	Low Vitamin D in Narcolepsy with Cataplexy. PLoS ONE, 2011, 6, e20433.	2.5	30
197	How our Dreams Changed During the COVID-19 Pandemic: Effects and Correlates of Dream Recall Frequency - a Multinational Study on 19,355 Adults. Nature and Science of Sleep, 2021, Volume 13, 1573-1591.	2.7	30
198	Sodium oxybate is an effective and safe treatment for narcolepsy. Sleep Medicine, 2010, 11, 105-106.	1.6	29

#	ARTICLE	IF	CITATIONS
199	Daytime somnolence in adult sleepwalkers. Sleep Medicine, 2013, 14, 1187-1191.	1.6	29
200	Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment. CNS Drugs, 2017, 31, 821-834.	5.9	29
201	Restless legs syndrome and cardiovascular diseases: A case-control study. PLoS ONE, 2017, 12, e0176552.	2.5	29
202	Disrupted nighttime sleep and sleep instability in narcolepsy. Journal of Clinical Sleep Medicine, 2022, 18, 289-304.	2.6	29
203	Narcolepsy Severity Scale: a reliable tool assessing symptom severity and consequences. Sleep, 2020, 43, .	1.1	29
204	Restless legs syndrome in narcolepsy: A side effect of sodium oxybate?. Sleep Medicine, 2007, 8, 181-183.	1.6	28
205	Preliminary results on CSF biomarkers for hypothalamic dysfunction in Kleineâ€“Levin syndrome. Sleep Medicine, 2015, 16, 194-196.	1.6	28
206	Circadian Rhythm Disturbances in the Blind. Current Neurology and Neuroscience Reports, 2018, 18, 65.	4.2	28
207	Rare missense mutations in P2RY11 in narcolepsy with cataplexy. Brain, 2017, 140, 1657-1668.	7.6	27
208	Predicting daytime sleepiness and fatigue: a 9-year prospective study in myotonic dystrophy type 1. Journal of Neurology, 2020, 267, 461-468.	3.6	27
209	Loss of the transcription factor Meis1 prevents sympathetic neurons target-field innervation and increases susceptibility to sudden cardiac death. ELife, 2016, 5, .	6.0	27
210	Risk Factors for Phenoconversion in <scp>Rapid Eye Movement</scp> Sleep Behavior Disorder. Annals of Neurology, 2022, 91, 404-416.	5.3	27
211	Decision making in restless legs syndrome. Movement Disorders, 2010, 25, 2634-2640.	3.9	26
212	Effect of Psychostimulants on Impulsivity and Risk Taking in Narcolepsy with Cataplexy. Sleep, 2013, 36, 1335-1340.	1.1	26
213	Excessive Sleepiness and Longer Nighttime in Bed Increase the Risk of Cognitive Decline in Frail Elderly Subjects: The MAPT-Sleep Study. Frontiers in Aging Neuroscience, 2017, 9, 312.	3.4	26
214	[18F]Fludeoxyglucose-Positron Emission Tomography Evidence for Cerebral Hypermetabolism in the Awake State in Narcolepsy and Idiopathic Hypersomnia. Frontiers in Neurology, 2017, 8, 350.	2.4	26
215	The distinguishing motor features of cataplexy: a study from video-recorded attacks. Sleep, 2018, 41, .	1.1	26
216	Update on treatment for idiopathic hypersomnia. Expert Opinion on Investigational Drugs, 2018, 27, 187-192.	4.1	26

#	Article	IF	Citations
217	Depression and suicidal thoughts in untreated and treated narcolepsy. Neurology, 2020, 95, e2755-e2768.	1.1	26
218	Maintenance of wakefulness test: how does it predict accident risk in patients with sleep disorders?. Sleep Medicine, 2021, 77, 249-255.	1.6	26
219	Kleine-Levin syndrome is associated with birth difficulties and genetic variants in the TRANK1 gene loci. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	26
220	Hypocretin and Human African Trypanosomiasis. Sleep, 2008, 31, 348-354.	1.1	25
221	Effects of 1â€month withdrawal of ventilatory support in hypercapnic myotonic dystrophy type 1. Respirology, 2017, 22, 1416-1422.	2.3	25
222	The dementia-associated APOE Îµ4 allele is not associated with rapid eye movement sleep behavior disorder. Neurobiology of Aging, 2017, 49, 218.e13-218.e15.	3.1	25
223	Association between serum hepcidin level and restless legs syndrome. Movement Disorders, 2018, 33, 618-627.	3.9	25
224	LRRK2 protective haplotype and full sequencing study in REM sleep behavior disorder. Parkinsonism and Related Disorders, 2018, 52, 98-101.	2.2	25
225	Differences in Brain Morphological Findings between Narcolepsy with and without Cataplexy. PLoS ONE, 2013, 8, e81059.	2.5	25
226	Effect of sodium oxybate, modafinil, and their combination on disrupted nighttime sleep in narcolepsy. Sleep Medicine, 2017, 40, 53-57.	1.6	24
227	Clinical autonomic dysfunction in narcolepsy type 1. Sleep, 2019, 42, .	1.1	24
228	Association of CSF orexin-A levels and nocturnal sleep stability in patients with hypersomnolence. Neurology, 2020, 95, e2900-e2911.	1.1	24
229	A systematic analysis of ICSD-3 diagnostic criteria and proposal for further structured iteration. Sleep Medicine Reviews, 2021, 58, 101439.	8.5	24
230	The orexin story, sleep and sleep disturbances. Journal of Sleep Research, 2022, 31, .	3.2	24
231	The Genetic Basis of Sleep Disorders. Current Pharmaceutical Design, 2008, 14, 3386-3395.	1.9	23
232	Olfactory dysfunction in narcolepsy with cataplexy. Sleep Medicine, 2010, 11, 876-881.	1.6	23
233	Melanin concentrating hormone in central hypersomnia. Sleep Medicine, 2011, 12, 768-772.	1.6	23
234	Restless legs syndrome and iron deficiency in adults with attention-deficit/hyperactivity disorder. Sleep, 2019, 42, .	1.1	23

#	Article	IF	Citations
235	Severity of Narcolepsy Among French of Different Ethnic Origins (South of France and Martinique). Sleep, 2002, 25, 50-55.	1.1	22
236	Pharmacogenomics in the treatment of narcolepsy. Pharmacogenomics, 2003, 4, 23-33.	1.3	22
237	Pharmacotherapy options for cataplexy. Expert Opinion on Pharmacotherapy, 2013, 14, 895-903.	1.8	22
238	Impulse control disorder and rapid eye movement sleep behavior disorder in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 1411-1414.	2.2	22
239	MEIS1 variant as a determinant of autonomic imbalance in Restless Legs Syndrome. Scientific Reports, 2017, 7, 46620.	3.3	22
240	Cardiac Sympathetic Activity differentiates Idiopathic and Symptomatic Rapid Eye Movement Sleep Behaviour Disorder. Scientific Reports, 2018, 8, 7304.	3.3	22
241	Blood pressure profile and endothelial function in restless legs syndrome. Scientific Reports, 2019, 9, 15933.	3.3	22
242	Maintenance of Wakefulness Test, real and simulated driving in patients with narcolepsy/hypersomnia. Sleep Medicine, 2019, 55, 1-5.	1.6	22
243	Narcolepsy with cataplexy: Does age at diagnosis change the clinical picture?. CNS Neuroscience and Therapeutics, 2020, 26, 1092-1102.	3.9	22
244	Arousal reactions in sleepwalking and night terrors in adults: the role of respiratory events. Sleep, 2002, 25, 871-5.	1.1	22
245	Dissociation in circadian rhythms in a pseudohypersomnia form of fatal familial insomnia. Neurology, 2004, 63, 2416-2418.	1.1	21
246	Narcolepsy and familial advanced sleep-phase syndrome: molecular genetics of sleep disorders. Current Opinion in Genetics and Development, 2007, 17, 222-227.	3.3	21
247	Risk Factor Profile in Parkinsonâ€™s Disease Subtype with REM Sleep Behavior Disorder. Journal of Parkinson's Disease, 2016, 6, 231-237.	2.8	21
248	Disorders of Arousal in adults: new diagnostic tools for clinical practice. Sleep Science and Practice, 2019, 3, .	1.3	21
249	Impaired histaminergic neurotransmission in children with narcolepsy type 1. CNS Neuroscience and Therapeutics, 2019, 25, 386-395.	3.9	21
250	Hepcidin and ferritin levels in restless legs syndrome: a caseâ€“control study. Scientific Reports, 2020, 10, 11914.	3.3	21
251	Characteristics associated with hypersomnia and excessive daytime sleepiness identified by extended polysomnography recording. Sleep, 2021, 44, .	1.1	21
252	Social Jetlag Changes During the COVID-19 Pandemic as a Predictor of Insomnia â€“ A Multi-National Survey Study. Nature and Science of Sleep, 2021, Volume 13, 1711-1722.	2.7	21

#	ARTICLE	IF	CITATIONS
253	Disturbances in sleep, circadian rhythms and daytime functioning in relation to coronavirus infection and Longâ€COVID â€“ A multinational ICOSS study. Journal of Sleep Research, 2022, 31, e13542.	3.2	21
254	Common and rare GCH1 variants are associated with Parkinson'sÂdisease. Neurobiology of Aging, 2019, 73, 231.e1-231.e6.	3.1	20
255	Gut microbiota composition is associated with narcolepsy type 1. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	20
256	Efficacy of THN102 (a combination of modafinil and flecainide) on vigilance and cognition during 40â€hour total sleep deprivation in healthy subjects: Glial connexins as a therapeutic target. British Journal of Clinical Pharmacology, 2019, 85, 2623-2633.	2.4	19
257	Analysis of common and rare VPS13C variants in late-onset Parkinson disease. Neurology: Genetics, 2020, 6, 385.	1.9	19
258	Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease. Neurobiology of Aging, 2021, 100, 119.e7-119.e13.	3.1	19
259	REVERSAL OF SYMPTOMATIC TUMORAL NARCOLEPSY, WITH NORMALIZATION OF CSF HYPOCRETIN LEVEL. Neurology, 2007, 69, 1300-1301.	1.1	18
260	C9orf72 Repeat Expansions in Rapid Eye Movement Sleep Behaviour Disorder. Canadian Journal of Neurological Sciences, 2014, 41, 759-762.	0.5	18
261	Impact of sleep disturbances on kidney function decline in the elderly. European Respiratory Journal, 2016, 47, 860-868.	6.7	18
262	Absence of Relationship Between Self-Reported Sleep Measures and Amyloid Load in Elderly Subjects. Frontiers in Neurology, 2019, 10, 989.	2.4	18
263	Reduced brain amyloid burden in elderly patients with narcolepsy type 1. Annals of Neurology, 2019, 85, 74-83.	5.3	18
264	Association of Inattention, Hyperactivity, and Hypersomnolence in Two Clinic-Based Adult Cohorts. Journal of Attention Disorders, 2020, 24, 555-564.	2.6	18
265	Measurement of Narcolepsy Symptoms in School-Aged Children and Adolescents. Neurology, 2021, 97, e476-e488.	1.1	18
266	Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy. Sleep, 2022, 45, .	1.1	18
267	Idling for Decades: A European Study on Risk Factors Associated with the Delay Before a Narcolepsy Diagnosis. Nature and Science of Sleep, 0, Volume 14, 1031-1047.	2.7	18
268	Cortico-Amygdala-Striatal Activation by Modafinil/Flecainide Combination. International Journal of Neuropsychopharmacology, 2018, 21, 687-696.	2.1	17
269	Complex HLA association in paraneoplastic cerebellar ataxia with anti-Yo antibodies. Journal of Neuroimmunology, 2018, 315, 28-32.	2.3	17
270	A provisional tool for the measurement of sleep satisfaction. Sleep Health, 2018, 4, 6-12.	2.5	17

#	Article	IF	Citations
271	Effects of an individualized exercise training program on severity markers of obstructive sleep apnea syndrome: a randomised controlled trial. Sleep Medicine, 2020, 70, 33-42.	1.6	17
272	Hypocretin/Orexin, Sleep and Alzheimerâ€™s Disease. Frontiers of Neurology and Neuroscience, 2021, 45, 139-149.	2.8	17
273	Narcolepsy and Other Central Hypersomnias. CONTINUUM Lifelong Learning in Neurology, 2017, 23, 989-1004.	0.8	17
274	Data-Driven Phenotyping of Central Disorders of Hypersomnolence With Unsupervised Clustering. Neurology, 2022, 98, .	1.1	17
275	Impact of genioplasty on mandibular growth during puberty. International Orthodontics, 2010, 8, 342-359.	1.9	16
276	Sequencing of the GBA coactivator, Saposin C, in Parkinson disease. Neurobiology of Aging, 2018, 72, 187.e1-187.e3.	3.1	16
277	Trajectories of Sleep Complaints From Early Midlife to Old Age: Longitudinal Modeling Study. Sleep, 2012, 35, 1559-68.	1.1	15
278	Cerebrospinal fluid monoamine levels in central disorders of hypersomnolence. Sleep, 2021, 44, .	1.1	15
279	Metabolomics Signature of Patients With Narcolepsy. Neurology, 2022, 98, .	1.1	15
280	Dual orexin receptor antagonist induces changes in core body temperature in rats after exercise. Scientific Reports, 2019, 9, 18432.	3.3	14
281	Sleep inertia measurement with the psychomotor vigilance task in idiopathic hypersomnia. Sleep, 2022, 45, .	1.1	14
282	Narcolepsy with intermediate cerebrospinal level of hypocretin-1. Sleep, 2022, 45, .	1.1	14
283	Exploration of cardiac sympathetic adrenergic nerve activity in narcolepsy. Clinical Neurophysiology, 2019, 130, 412-418.	1.5	13
284	Variants in the Niemannâ€“Pick type C gene NPC1 are not associated with Parkinson's disease. Neurobiology of Aging, 2020, 93, 143.e1-143.e4.	3.1	13
285	Video-Polysomnographic Assessment for the Diagnosis of Disorders of Arousal in Children. Neurology, 2021, 96, e121-e130.	1.1	13
286	Influenza vaccination induces autoimmunity against orexinergic neurons in a mouse model for narcolepsy. Brain, 2022, 145, 2018-2030.	7.6	13
287	Sleep and dementia. Journal of Nutrition, Health and Aging, 2010, 14, 201-202.	3.3	12
288	The role of the melanoma gene MC1R in Parkinson disease and REM sleep behavior disorder. Neurobiology of Aging, 2016, 43, 180.e7-180.e13.	3.1	12

#	Article	IF	Citations
289	Vitamin D deficiency in type 1 narcolepsy: a reappraisal. Sleep Medicine, 2017, 29, 1-6.	1.6	12
290	French consensus. Hypersomnolence: Evaluation and diagnosis. Revue Neurologique, 2017, 173, 19-24.	1.5	12
291	Kleineâ€Levin syndrome is associated with LMOD3 variants. Journal of Sleep Research, 2019, 28, e12718.	3.2	12
292	Novel Associations of BST1 and LAMP3 With REM Sleep Behavior Disorder. Neurology, 2021, 96, e1402-e1412.	1.1	12
293	Complaints of daytime sleepiness, insomnia, hypnotic use, and risk of dementia: a prospective cohort study in the elderly. Alzheimer's Research and Therapy, 2022, 14, 12.	6.2	12
294	Autoantibody profiling on high-density protein microarrays for biomarker discovery in the cerebrospinal fluid. Journal of Immunological Methods, 2008, 338, 75-78.	1.4	11
295	French consensus. Idiopathic hypersomnia: Investigations and follow-up. Revue Neurologique, 2017, 173, 32-37.	1.5	11
296	TOX3 Variants Are Involved in Restless Legs Syndrome and Parkinsonâ€™s Disease with Opposite Effects. Journal of Molecular Neuroscience, 2018, 64, 341-345.	2.3	11
297	Comprehensive Analysis of Familial Parkinsonism Genes in Rapidâ€Eyeâ€Movement Sleep Behavior Disorder. Movement Disorders, 2021, 36, 235-240.	3.9	11
298	New 2013 incidence peak in childhood narcolepsy: more than vaccination?. Sleep, 2021, 44, .	1.1	11
299	Idiopathic Hypersomnia Severity Scale to better quantify symptoms severity and their consequences in idiopathic hypersomnia. Journal of Clinical Sleep Medicine, 2022, 18, 617-629.	2.6	11
300	Persistence of deep-tendon reflexes during partial cataplexy. Sleep Medicine, 2018, 45, 80-82.	1.6	10
301	Impaired glycinergic transmission in hyperekplexia: a model of parasomnia overlap disorder. Annals of Clinical and Translational Neurology, 2019, 6, 1900-1904.	3.7	10
302	Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Participants with Narcolepsy with and without Cataplexy: Subgroup Analysis of Efficacy and Safety Data by Cataplexy Status in a Randomized Controlled Trial. CNS Drugs, 2020, 34, 773-784.	5.9	10
303	Linking clinical complaints and objective measures of disrupted nighttime sleep in narcolepsy type 1. Sleep, 2022, 45, .	1.1	10
304	Dreamâ€enactment behaviours during the <scp>COVID</scp>â€19 pandemic: an international <scp>COVID</scp>â€19 sleep study. Journal of Sleep Research, 2023, 32, .	3.2	10
305	Facial expression recognition and emotional regulation in narcolepsy with cataplexy. Journal of Sleep Research, 2013, 22, 170-177.	3.2	9
306	Is adult-onset attention deficit/hyperactivity disorder frequent in clinical practice?. Psychiatry Research, 2017, 257, 238-241.	3.3	9

#	Article	IF	Citations
307	Association study of essential tremor genetic loci in Parkinson'sÂdisease. Neurobiology of Aging, 2018, 66, 178.e13-178.e15.	3.1	9
308	CSF and serum ferritin levels in narcolepsy type 1 comorbid with restless legs syndrome. Annals of Clinical and Translational Neurology, 2020, 7, 924-931.	3.7	9
309	A series of 8 cases of sleep-related psychogenic dissociative disorders and proposed updated diagnostic criteria. Journal of Clinical Sleep Medicine, 2022, 18, 563-573.	2.6	9
310	Comorbid parasomnias in narcolepsy and idiopathic hypersomnia: more REM than NREM parasomnias. Journal of Clinical Sleep Medicine, 2022, 18, 1355-1364.	2.6	9
311	Depressive Symptoms and Suicidal Thoughts in Restless Legs Syndrome. Movement Disorders, 2022, 37, 812-825.	3.9	9
312	Circulating follicular helper T cells exhibit reduced ICOS expression and impaired function in narcolepsy type 1 patients. Journal of Autoimmunity, 2018, 94, 134-142.	6.5	8
313	Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial. CNS Drugs, 2022, 36, 377-387.	5.9	8
314	Ventilatory disorders and facial growth: Benefits of early genioplasty. International Orthodontics, 2011, 9, 20-41.	1.9	7
315	Rhythmic movement disorder associated with restless legs syndrome. Sleep Medicine, 2012, 13, 1324-1325.	1.6	7
316	Ictal SPECT in patients with rapid eye movement sleep behaviour disorder. Brain, 2015, 138, e390-e390.	7.6	7
317	Shared T cell receptor chains in blood memory CD4+ T cells of narcolepsy type 1 patients. Journal of Autoimmunity, 2019, 100, 1-6.	6.5	7
318	French Language Online Cognitive Behavioral Therapy for Insomnia Disorder: A Randomized Controlled Trial. Frontiers in Neurology, 2019, 10, 1273.	2.4	7
319	Validation of the French Version of the Weiss Functional Impairment Rating Scaleâ€“Self-Report in a Large Cohort of Adult Patients With ADHD. Journal of Attention Disorders, 2019, 23, 1148-1159.	2.6	7
320	Increased blood pressure during the suggested immobilization test in Restless Legs Syndrome. Sleep, 2020, 43, .	1.1	7
321	Increased Blood Pressure Dipping in Restless Legs Syndrome With Rotigotine: A Randomized Trial. Movement Disorders, 2020, 35, 2164-2173.	3.9	7
322	Disturbed nighttime sleep in children and adults with rhythmic movement disorder. Sleep, 2020, 43, .	1.1	7
323	Sleep-related head jerks: toward a new movement disorder. Sleep, 2021, 44, .	1.1	7
324	Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications. CNS Drugs, 2022, 36, 633-647.	5.9	7

#	ARTICLE	IF	CITATIONS
325	Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients. Journal of Clinical Sleep Medicine, 2022, 18, 2217-2227.	2.6	7
326	Time to find a biomarker in Kleineâ€“Levin Syndrome. Sleep Medicine, 2016, 21, 177.	1.6	6
327	Clinical neurophysiology of CNS hypersomnias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 161, 353-367.	1.8	6
328	Systematic assessment of autonomic symptoms in restless legs syndrome. Sleep Medicine, 2021, 80, 30-38.	1.6	6
329	Self-perceived sleep during the Maintenance of Wakefulness Test: how does it predict accidental risk in patients with sleep disorders?. Sleep, 2021, 44, .	1.1	6
330	<scp>THN</scp> 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial. Movement Disorders, 2022, 37, 410-415.	3.9	6
331	Is Restless Legs Syndrome Involved in Ambulation Related to Sleepwalking?. Sleep, 2016, 39, 955-956.	1.1	5
332	RIC3 variants are not associated with Parkinson's disease in French-Canadians and French. Neurobiology of Aging, 2017, 53, 194.e9-194.e11.	3.1	5
333	Low cerebrospinal fluid hypocretin levels during sudden infant death syndrome (SIDS) risk period. Sleep Medicine, 2017, 33, 57-60.	1.6	5
334	Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. Brain, 2017, 140, e32-e32.	7.6	5
335	Kinesthetic stimulation for obstructive sleep apnea syndrome: An â€œon-offâ€•proof of concept trial. Scientific Reports, 2018, 8, 3092.	3.3	5
336	Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy. Journal of Clinical Sleep Medicine, 2022, 18, 235-244.	2.6	5
337	Symptom network analysis of the sleep disorders diagnostic criteria based on the clinical text of the ICSDâ€3. Journal of Sleep Research, 2022, 31, e13435.	3.2	5
338	Histamine in murine narcolepsy: What do genetic and immune models tell us?. Brain Pathology, 2022, 32, e13027.	4.1	5
339	Idiopathic Hypersomnia. , 2011, , 969-979.		4
340	Altered Sleep-Related Blood Pressure Profile in Hypocretin-Deficient Narcoleptic Patients. Sleep, 2012, 35, 453-454.	1.1	4
341	Is the Muscle the Only Potential Target of Desipramine in Obstructive Sleep Apnea Syndrome?. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1677-1678.	5.6	4
342	Knowledge Gaps in the Perioperative Management of Adults With Narcolepsy. Anesthesia and Analgesia, 2019, 129, 204-211.	2.2	4

#	ARTICLE	IF	CITATIONS
343	Reply to Micoulaud-Franchi etÂal. Commentary on diagnosis of central disorders of hypersomnolence: From clinic to clinic via ontology and semantic analysis on a bullet point path. Sleep Medicine Reviews, 2020, 52, 101329.	8.5	4
344	Reply to Maski K etÂal. commentary on diagnosis of central disorders of hypersomnolence: Challenges in defining central disorders of hypersomnolence. Sleep Medicine Reviews, 2020, 52, 101326.	8.5	4
345	2018 worldwide survey of health-care providers caring for patients with narcolepsy. Sleep Medicine, 2021, 82, 23-28.	1.6	4
346	SMPD1 variants do not have a major role in rapid eye movement sleep behavior disorder. Neurobiology of Aging, 2020, 93, 142.e5-142.e7.	3.1	4
347	Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials. CNS Drugs, 2021, 35, 1303-1315.	5.9	4
348	Does the adenosine deaminase (ADA) gene confer risk of sleepwalking?. Journal of Sleep Research, 2022, 31, e13537.	3.2	4
349	Current and future therapeutic approaches in narcolepsy. Future Neurology, 2011, 6, 771-782.	0.5	3
350	Heritability in chronic insomnia. Sleep Medicine, 2012, 13, 969-970.	1.6	3
351	Identifying the best biomarkers for Î±-synucleinopathies. Lancet Neurology, The, 2021, 20, 593-594.	10.2	3
352	Rare PSAP Variants and Possible Interaction with GBA in REM Sleep Behavior Disorder. Journal of Parkinson's Disease, 2022, 12, 333-340.	2.8	3
353	Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy. Nature and Science of Sleep, 2022, Volume 14, 531-546.	2.7	3
354	Comment on the Letter to the Editor By Dr. Marcus on the Association between Narcolepsy and H1N1 Exposure. Sleep, 2011, 34, 689-690.	1.1	2
355	Excessive daytime sleepiness and antipathogen drug consumption in the elderly: a test of the immune theory of sleep. Scientific Reports, 2016, 6, 23574.	3.3	2
356	Idiopathic Hypersomnia. , 2017, , 883-891.e4.		2
357	489 Pivotal Phase 3 Study of FT218, a Once-Nightly Sodium Oxybate Formulation, in Patients With Narcolepsy: REST-ON Primary Results. Sleep, 2021, 44, A193-A193.	1.1	2
358	Diurnal and Nocturnal Sleep in Narcolepsy with Cataplexy. , 2010, , 77-85.		2
359	Prognostic Impact of Sleep Patterns and Related-Drugs in Patients with Heart Failure. Journal of Clinical Medicine, 2021, 10, 5387.	2.4	2
360	0393 Weight Changes During Treatment With Lower-Sodium Oxybate in a Phase 3 Clinical Study in Patients With Narcolepsy. Sleep, 2022, 45, A176-A176.	1.1	2

#	Article	IF	Citations
361	To Increase Our Knowledge on Sleep, Sleep Disorders, and Chronobiology in the Neuroscience Field during the Next Decade. Frontiers in Neurology, 2017, 8, 16.	2.4	1
362	Multiple treatment comparison in narcolepsy: a network meta-analysisâ€"methodological concerns. Sleep, 2019, 42, .	1.1	1
363	Responsiveness of Daytime Sleepiness and Fatigue Scales in Myotonic Dystrophy Type 1. Canadian Journal of Neurological Sciences, 2022, 49, 287-290.	0.5	1
364	344 Daridorexant Improves Total Sleep Time (TST) in Insomnia Patients Without Altering the Proportion of Sleep Stages. Sleep, 2021, 44, A137-A138.	1.1	1
365	485 Efficacy and Safety of Once- and Twice-Nightly Dosing of Lower-Sodium Oxybate in Adults With Idiopathic Hypersomnia. Sleep, 2021, 44, A191-A192.	1.1	1
366	500 Correlation of the Idiopathic Hypersomnia Severity Scale With Other Measures of Sleep Parameters in a Phase 3 Trial. Sleep, 2021, 44, A197-A197.	1.1	1
367	494 Placebo-Controlled, Double-Blind, Randomized Withdrawal Study of Lower-Sodium Oxybate in Adults With Idiopathic Hypersomnia. Sleep, 2021, 44, A195-A195.	1.1	1
368	Narcolepsy, Idiopathic Hypersomnia, and Dysautonomia. , 2021, , 187-198.		1
369	Human and Animal Genetics of Sleep and Sleep Disorders. , 2009, , 295-306.		1
370	Parasomnias in Narcolepsy with Cataplexy. , 2011, , 291-299.		1
371	0387 Weight Changes During Treatment With Lower-Sodium Oxybate in a Phase 3 Clinical Study in Patients With Idiopathic Hypersomnia. Sleep, 2022, 45, A173-A174.	1.1	1
372	Hypocretin in Neuropsychiatric Disorders. , 2005, , 263-277.		0
373	Comments on the Letter to the Editor by Ferri et al. on Autonomic Response to Periodic Leg Movements in Sleep in Narcolepsy-Cataplexy. Sleep, 2011, 34, 411-412.	1.1	0
374	Conflicts of Interestâ€"Reply. Archives of General Psychiatry, 2012, 69, 1181.	12.3	0
375	Decision making and addictive behaviors in narcolepsy with cataplexy. Sleep and Biological Rhythms, 2013, 11, 62-64.	1.0	0
376	Treatment options in narcolepsy. Expert Opinion on Orphan Drugs, 2013, 1, 987-999.	0.8	0
377	Editorial. Revue Neurologique, 2017, 173, 6-7.	1.5	0
378	Author response: Comorbidity between central disorders of hypersomnolence and immune-based disorders. Neurology, 2017, 88, 1777-1777.	1.1	0

#	ARTICLE	IF	CITATIONS
379	Reply to â€œRigor, reproducibility and in vitro CSF assays: The devil in the detailsâ€• Annals of Neurology, 2017, 81, 907-910.	5.3	0
380	Reliability of wristâ€worn accelerometry devices and algorithms for sleep detection. Alzheimer's and Dementia, 2020, 16, e042808.	0.8	0
381	490 Efficacy of FT218 on Polysomnographic Measures of Sleep Continuity in Patients With Narcolepsy: Results From the REST-ON Trial. Sleep, 2021, 44, A193-A194.	1.1	0
382	487 Effect of Lower-Sodium Oxybate on Sleep Inertia in Idiopathic Hypersomnia in a Double-Blind, Randomized Withdrawal Study. Sleep, 2021, 44, A192-A192.	1.1	0
383	495 Efficacy of Lower-Sodium Oxybate on Idiopathic Hypersomnia, Measured by the Idiopathic Hypersomnia Severity Scale. Sleep, 2021, 44, A195-A195.	1.1	0
384	488 REST-ON: Efficacy of FT218 for Daytime Sleepiness, Sleep Quality, Hallucinations, and Sleep Paralysis in Patients With Narcolepsy. Sleep, 2021, 44, A192-A193.	1.1	0
385	REM Sleep Behavior Disorder in Narcolepsy with Cataplexy. , 2010, , 99-103.		0
386	Diagnostic Algorithm for Hypersomnias. , 2008, , 277-297.		0
387	Aspectos genÃ©ticos y trastornos del sueÃ±o en el ser humano y en los animales de experimentaciÃ³n. , 2011, , 295-306.		0
388	Narcolepsie : Lien avec lâ€™infection et la vaccination antigrippale H1N1 ?. Bulletin De L'Academie Nationale De Medecine, 2016, 200, 1191-1201.	0.0	0
389	Genetics of Sleep and Sleep Disorders. , 2017, , 523-537.		0
390	Narcolepsy with Cataplexy: Hypocretin and Immunological Aspects. , 2007, , 337-352.		0
391	Device agnostic sleep-wake segment classification from wrist-worn accelerometry. , 2020, , .		0
392	0389 Efficacy of Lower-Sodium Oxybate in the Treatment of Idiopathic Hypersomnia: Evaluation of Response Based on the Epworth Sleepiness Scale Score. Sleep, 2022, 45, A174-A175.	1.1	0
393	0390 Efficacy of Lower-Sodium Oxybate in the Treatment of Idiopathic Hypersomnia: Evaluation of Response Based on the Idiopathic Hypersomnia Severity Scale Score. Sleep, 2022, 45, A175-A175.	1.1	0